Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scolr Pharma has entered into a collaboration and license agreement with Dr Reddy's Laboratories to pursue the development and commercialization of an undisclosed oral prescription drug for the cardiopulmonary market.
Subscribe to our email newsletter
Under the terms of the agreement, Dr Reddy’s will be responsible for the development, manufacturing and marketing of the drug product, which will utilize Scolr’s CDT technology. Scolr Pharma will be responsible for the formulation and assisting with product scale-up activities.
The agreement provides double-digit participation in net profits for Scolr Pharma after recovery of development and commercialization expenses associated with the potential product, according to the US-based company. Other financial terms of the agreement have not been disclosed.